PL2018169T3 - Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków - Google Patents

Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków

Info

Publication number
PL2018169T3
PL2018169T3 PL07725140T PL07725140T PL2018169T3 PL 2018169 T3 PL2018169 T3 PL 2018169T3 PL 07725140 T PL07725140 T PL 07725140T PL 07725140 T PL07725140 T PL 07725140T PL 2018169 T3 PL2018169 T3 PL 2018169T3
Authority
PL
Poland
Prior art keywords
dihydroxyandrost
ene
beta
treating cancers
hormone
Prior art date
Application number
PL07725140T
Other languages
English (en)
Inventor
Alexander Tobias Teichmann
Original Assignee
Mabel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabel Gmbh filed Critical Mabel Gmbh
Publication of PL2018169T3 publication Critical patent/PL2018169T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07725140T 2006-05-12 2007-05-11 Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków PL2018169T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74712406P 2006-05-12 2006-05-12
EP06009894A EP1854465A1 (en) 2006-05-12 2006-05-12 Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
EP07725140A EP2018169B1 (en) 2006-05-12 2007-05-11 Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
PCT/EP2007/004220 WO2007131736A2 (en) 2006-05-12 2007-05-11 Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers

Publications (1)

Publication Number Publication Date
PL2018169T3 true PL2018169T3 (pl) 2011-04-29

Family

ID=37075285

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07725140T PL2018169T3 (pl) 2006-05-12 2007-05-11 Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków
PL07725141T PL2018170T3 (pl) 2006-05-12 2007-05-11 Lek na raka sutka

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07725141T PL2018170T3 (pl) 2006-05-12 2007-05-11 Lek na raka sutka

Country Status (15)

Country Link
US (3) US9138477B2 (pl)
EP (3) EP1854465A1 (pl)
JP (2) JP5363310B2 (pl)
KR (2) KR101403893B1 (pl)
CN (2) CN101443016B (pl)
AT (1) ATE487483T1 (pl)
AU (2) AU2007251823B2 (pl)
CA (2) CA2651354C (pl)
DE (1) DE602007010447D1 (pl)
DK (2) DK2018169T3 (pl)
ES (2) ES2391839T3 (pl)
PL (2) PL2018169T3 (pl)
PT (2) PT2018169E (pl)
SI (2) SI2018170T1 (pl)
WO (2) WO2007131737A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854465A1 (en) 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
ES2574933T3 (es) * 2007-11-13 2016-06-23 Athenion Ag Esteroides de C-19 para usos cosméticos
ES2628507T3 (es) 2007-11-13 2017-08-03 Athenion Ag Esteroides C-19 para el tratamiento de la celulitis
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
AU2011308775B2 (en) * 2010-10-01 2016-11-17 Indiana University Research And Technology Corporation Treatment of symptoms associated with menopause
JP6091431B2 (ja) * 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用
WO2015055179A1 (de) * 2013-10-15 2015-04-23 Chelac Holding Gmbh Steroid-carbonsäureester, zusammensetzungen, enthaltend steroid-carbonsäureester und verwendung dieser bei lokal topischer applikation für kosmetische oder dermatologische zwecke
SI3040075T1 (en) * 2014-12-30 2018-04-30 Curadis Gmbh C-19 STEROIDS FOR INHIBITION OF NEVASCULARIZATION
US20190201526A1 (en) * 2016-09-07 2019-07-04 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells
CN108727453A (zh) * 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
EP3632445A1 (en) * 2018-10-04 2020-04-08 Curadis GmbH Combinations with a c-19 steroid for treating cancers
RU2679625C1 (ru) * 2018-11-08 2019-02-12 Ильясов Шамиль Сионович ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ
EP3666276A1 (en) 2018-12-14 2020-06-17 dcic Biopharmaceutical Limited Medication against estrogen-receptor beta (erbeta) positive breast tumor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA639855A (en) 1962-04-17 Societa Farmaceutici Italia 4-halo-3-keto-.delta.4-steroids
BE552152A (pl) *
US2744120A (en) 1953-01-14 1956-05-01 Olin Mathieson 1-dehydrotestololactone
US2762818A (en) * 1955-05-26 1956-09-11 Searle & Co 4-hydroxytestosterone and esters thereof
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
US4289762A (en) 1980-06-27 1981-09-15 Merrell Dow Pharmaceuticals Inc. 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
US4322416A (en) * 1980-06-27 1982-03-30 Merrell Dow Pharmaceuticals Inc. 10-Alkynyl steroids
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3362176D1 (en) 1982-07-14 1986-03-27 Akzo Nv Novel 19-thio-androstane derivatives
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
US20030229063A1 (en) * 2002-06-05 2003-12-11 Llewellyn William Charles Use of 4-hydroxytestosterone to lower estrogen levels in humans
US20030049307A1 (en) * 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
GB2398495B (en) * 2003-01-23 2007-08-22 Kent G Lau A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug
TW200510384A (en) * 2003-08-07 2005-03-16 Schering Corp Novel farnesyl protein transferase inhibitors as antitumor agents
CA2542096A1 (en) 2003-10-09 2005-04-21 Aton Pharma, Inc. Thiophene and benzothiophene hydroxamic acid derivatives
WO2005062760A2 (en) * 2003-12-12 2005-07-14 University Of Rochester Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor
EP1802341A1 (en) 2004-07-16 2007-07-04 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EP1854465A1 (en) 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers

Also Published As

Publication number Publication date
PT2018170E (pt) 2012-10-25
ES2355530T3 (es) 2011-03-28
EP2018169B1 (en) 2010-11-10
AU2007251822A1 (en) 2007-11-22
EP2018169A2 (en) 2009-01-28
US9114163B2 (en) 2015-08-25
DK2018170T3 (da) 2012-10-22
KR20090010189A (ko) 2009-01-29
US20090111784A1 (en) 2009-04-30
WO2007131736A2 (en) 2007-11-22
PL2018170T3 (pl) 2013-01-31
CN101443017B (zh) 2013-07-31
WO2007131736A3 (en) 2008-03-06
US9138477B2 (en) 2015-09-22
KR20090009855A (ko) 2009-01-23
SI2018169T1 (sl) 2011-02-28
CA2651354C (en) 2015-11-17
JP5363310B2 (ja) 2013-12-11
JP2009536932A (ja) 2009-10-22
WO2007131737A3 (en) 2008-05-02
EP2018170B1 (en) 2012-07-25
CA2652057C (en) 2015-07-07
AU2007251823B2 (en) 2012-09-06
AU2007251822B2 (en) 2012-08-16
JP2009536931A (ja) 2009-10-22
KR101403893B1 (ko) 2014-06-20
EP2018170A2 (en) 2009-01-28
KR101403895B1 (ko) 2014-06-20
ATE487483T1 (de) 2010-11-15
CA2651354A1 (en) 2007-11-22
SI2018170T1 (sl) 2012-12-31
JP5363309B2 (ja) 2013-12-11
CA2652057A1 (en) 2007-11-22
US20100061975A1 (en) 2010-03-11
DK2018169T3 (da) 2011-02-07
DE602007010447D1 (de) 2010-12-23
AU2007251823A1 (en) 2007-11-22
EP1854465A1 (en) 2007-11-14
CN101443017A (zh) 2009-05-27
US9610292B2 (en) 2017-04-04
ES2391839T3 (es) 2012-11-30
CN101443016A (zh) 2009-05-27
US20160030448A1 (en) 2016-02-04
WO2007131737A2 (en) 2007-11-22
CN101443016B (zh) 2012-09-05
PT2018169E (pt) 2011-01-19

Similar Documents

Publication Publication Date Title
SI2018169T1 (sl) Uporaba 4,17 beta-dihidroksiandrost-4-en-3-ona za zdravljenje raka
TW200612892A (en) Novel compounds
TW200630336A (en) Novel compounds
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
TW200621690A (en) Novel compounds
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
TW200745003A (en) Novel compounds
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200732296A (en) Novel compounds
MXPA05010682A (es) Compuestos novedosos.
TW200519075A (en) Novel compounds
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200801029A (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TW200738659A (en) Novel compounds
TW200531689A (en) Therapeutic agents
GEP20074197B (en) 5ht2c receptor modulators
TW200635903A (en) Therapeutic agents
GB0611907D0 (en) Compounds
TW200633986A (en) Therapeutic agents
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine